Expert Interview
Discussing AstraZeneca's (via EsoBiotec platform) ESO-T01 (In Vivo Anti-BCMA CAR-T Therapy) for Relapsed/Refractory Multiple Myeloma Phase 1 Data
Ticker(s): AZNInstitution: Dana-Farber Cancer Institute and Harvard Medical School
- Program Director of the Jerome Lipper Multiple Myeloma Center; Kraft Family Professor of Medicine at Harvard Medical School
- Manages 500 patients per year with multiple myeloma, and 40-50 per year of those are treated with CAR-T
- Pioneered multiple myeloma research and therapeutics, with seminal contributions to the development of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and combination regimens that have transformed myeloma care. Leads and collaborates on landmark clinical trials and translational research focused on tumor microenvironment, drug resistance, and immune-based therapies; has authored 1,000+ peer-reviewed publications and plays a central role in international guidelines, advisory boards, and scientific leadership shaping the future of myeloma treatment
Are You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 21, 2026
- Call Time
- 03:00 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
